Validation of a Computational Histology Artificial Intelligence–based Biomarker for BCG Treatment in Non–muscle-invasive Bladder Cancer in the ANZUP 1301 Randomized Phase 3 Trial
Validation of a Computational Histology Artificial Intelligence–based Biomarker for BCG Treatment in Non–muscle-invasive Bladder Cancer in the ANZUP 1301 Randomized Phase 3 Trial. // European Urology. – URL: https://www.sciencedirect.com/science/article/pii/S0302283826024334?dgcid=rss_sd_all
Validation of a Computational Histology Artificial Intelligence–based Biomarker for BCG Treatment in Non–muscle-invasive Bladder Cancer in the ANZUP 1301 Randomized Phase 3 Trial. European Urology. https://www.sciencedirect.com/science/article/pii/S0302283826024334?dgcid=rss_sd_all
“Validation of a Computational Histology Artificial Intelligence–based Biomarker for BCG Treatment in Non–muscle-invasive Bladder Cancer in the ANZUP 1301 Randomized Phase 3 Trial.” European Urology.
@article{article89246,
title = {Validation of a Computational Histology Artificial Intelligence–based Biomarker for BCG Treatment in Non–muscle-invasive Bladder Cancer in the ANZUP 1301 Randomized Phase 3 Trial},
journal = {European Urology},
url = {https://www.sciencedirect.com/science/article/pii/S0302283826024334?dgcid=rss_sd_all}
}
Objective To assess prostate‐specific antigen (PSA) testing according to income, age, and region of residence in Sweden. Patients and Methods We conducted a nationwide, population‐based open cohort study of men aged 40–90 years in...